亚胺培南-西司他丁钠在腹膜透析相关腹膜炎后续治疗的疗效

目的 探讨亚胺培南-西司他丁钠作为腹膜透析相关性腹膜炎后续治疗的疗效.方法 以2007年1月至2010年12月在北京大学第三医院收治的并发腹膜透析相关性腹膜炎患者44例为对象.这些患者经过3d的初始治疗透析液仍未清亮,细菌培养结果是革兰阴性杆菌或阴性,其中13例次采用头孢他啶治疗；36例次采用亚胺培南-西司他丁钠治疗....

Efficacy of imipenem-cilastin sodium as subsequent therapy on peritoneal dialysis-related peritonitis

Objective To evaluate the efficacy of imipenem-cilastin sodium as subsequent therapy on peritoneal dialysis(PD)-related peritonitis. Methods From January 2007 to December 2010, 44 PD-related peritonitis patients in our hospital were enrolled in the study. These patients presented cloudy fluid after 3 days initial treatment, and bacterial culture was Gram-negative bacteria or negative. Thirteen peritonitis episodes were treated with ceftazidime, while 36 episodes with imipenem-cilastin sodium. Efficacy, outcome, pathogen and drug-resistance were analyzed retrospectively. Results The effective rates 2 d later of ceftazidime and imipenem-cilastin sodium were 23.1% and 72.2% respectively with significant difference (P<0.05). Gram-negative bacteria of ceftazidime and imipenem-cilastin sodium groups were 69.4% and 65.2% respectively without significant difference (P>0.05). The cure rates 3 weeks later of ceftazidime and imipenem-cilastin sodium groups were 23.1% and 72.2% respectively with significant difference (P<0.05). Conclusion As subsequent therapy for PD-related peritonitis, imipenem-cilastin sodium can improve the cure rate.